Shenzhen Gaozhuo Pharmaceutical

Shenzhen Gaozhuo Pharmaceutical Technology is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the discovery and development of innovative small molecule drugs. The company utilizes a proprietary structure-based drug design (SBDD) platform to create highly selective therapies for oncology and metabolic diseases. Its lead candidate, GZ-001, is a selective CDK4/6 inhibitor currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, including breast cancer. Gaozhuo Pharmaceutical is committed to addressing unmet clinical needs through the development of next-generation kinase inhibitors and targeted protein degradation (PROTAC) technologies. The firm has received significant backing from prominent Chinese venture capital firms, such as Shenzhen Capital Group and Green Pine Capital Partners, to advance its diversified pipeline. By focusing on precision medicine, Gaozhuo aims to provide high-quality and effective treatment options for patients globally.